CAS · 1350653-20-1
Product Overview
Vericiguat is a high-purity pharmaceutical-intermediates supplied for industrial and specialty chemical applications. Contact our team for specifications, packaging options and lead times.
Product Specifications
| Appearance | Off white to white solid |
|---|---|
| Assay | 98% min |
| Maximum single impurity | 0.2% max |
| Total impurities | 1.0% max |
| Loss on drying | 1.0% max |
| Residue on ignition | 0.5% max |
Applications
Vericiguat (CAS 1350653-20-1) is a pharmacologically active compound used primarily in cardiovascular medicine as a soluble guanylate cyclase (sGC) stimulator. Clinically, it is applied in the treatment of chronic heart failure with reduced ejection fraction (HFrEF), where it enhances cyclic guanosine monophosphate (cGMP) production, leading to vasodilation, reduced cardiac preload and afterload, and improved cardiac function. In research, vericiguat is employed to study sGC signaling pathways, cardiovascular disease mechanisms, and the development of novel therapeutics targeting the nitric oxide–cGMP pathway. Its use extends to preclinical studies investigating vascular protection, anti-fibrotic effects, and potential combination therapies for heart failure management.
Benefits
The benefits of vericiguat stem from its ability to selectively stimulate soluble guanylate cyclase, enhancing endogenous nitric oxide signaling and promoting cardiovascular homeostasis. By increasing cGMP levels, it improves vascular tone, reduces cardiac stress, and supports renal function without causing significant hypotension, offering a favorable safety profile. Its oral bioavailability and pharmacokinetic properties allow convenient administration and consistent therapeutic effects. Vericiguat also complements existing heart failure therapies, providing additive benefits in patients with high morbidity risk. Its mechanism of action represents a targeted approach to managing heart failure at the molecular signaling level, improving clinical outcomes.
Conclusion
In summary, vericiguat is an sGC stimulator used in the treatment of chronic heart failure and cardiovascular research. Its applications include improving cardiac function, vascular protection, and studying nitric oxide–cGMP signaling, while its benefits lie in selective enzyme stimulation, favorable safety, and synergistic effects with other heart failure therapies. With these characteristics, vericiguat is an important therapeutic agent and research tool in cardiovascular medicine.
Previous
Butyl 4-oxocyclohexane-1-carboxylate丨CAS 155561-32-3
Next